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Abstract
Background: Pancreatic cancer occurs more frequently in older patients, but these are underrepresented in the
phase III clinical studies that established the current treatment standards. This leads to uncertainty regarding the
treatment of older patients with potentially toxic but active regimens like FOLFIRINOX.
Methods: We conducted a retrospective analysis of patients treated according to the FOLFIRINOX protocol at our
institution between 2010 and 2014 with a focus on older patients.
Results: Overall survival in our cohort was 10.2 months. Only 43% of patients did not need dose adaptations, but
dose reductions did not lead to an inferior survival. We did not find evidence that patients aged 65 years and older
deemed fit enough for palliative treatment had more toxicities or a worse outcome than younger patients.
Conclusion: We conclude that treatment with the FOLFIRINOX protocol in patients with pancreatic cancer should
not be withhold from patients solely based on their chronological age but rather be based on the patient’s
performance status and comorbidities.
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Background
Cancer occurs more frequently in elderly people, and
the current demographic changes with an aging popula-
tion in Western countries will therefore result in a rising
incidence of cancer and an increasing amount of older
cancer patients [1–3]. For the US, it has been estimated
that by 2030, approximately 70% of all cancers will be
diagnosed in adults older than 65 years [4]. In contrast
to this development, older patients remain underrepre-
sented in the clinical cancer studies that establish stand-
ard treatment regimens [5]. There is widespread critique
concerning this issue, but to date, trial results have to be
extrapolated to the older population, although this
approach remains questionable [6]. Fear of increased
toxicities and uncertainty concerning both clinical treat-
ment benefit and the patient’s physical resources may
cause limitation of tumor-specific therapies in older
patients. Ensuring an adequate antitumor treatment
while avoiding toxicity is a challenging task for geriatric
oncology in daily routine.
For pancreatic adenocarcinoma, the fourth common
cause of cancer-related death in the US [7], approxi-
mately two-thirds of cases are diagnosed in patients over
65 years [8]. The overall 5-year survival rate is about 6%
and remains the poorest of all major malignancies [9, 10].
Because the majority of tumors is irresectable or recurs
after surgery, systemic palliative treatment is needed for
almost every patient [11]. Despite its limited activity,
single-agent gemcitabine was the standard palliative first-
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line treatment for patients with advanced disease for more
than a decade [12], until therapy options improved in
2011. In the landmark PRODIGE 4 trial, the FOLFIRI-
NOX protocol had an impressive response rate of 31.6%,
and it significantly improved median overall survival (OS)
from 6.8 months in the gemcitabine monotherapy arm to
11.1 months [13]. More recently, this protocol has also
been used successfully in patients with irresectable, locally
advanced disease to achieve resectability and therefore
offering a chance for cure [14]. The impressive results of
the FOLFIRINOX protocol are accompanied by signifi-
cantly increased grade 3 and 4 toxicities, mainly myelo-
suppression, diarrhea and peripheral neuropathy.
Concerns regarding safety in the palliative setting have
been raised immediately [15]. Likewise, the study popula-
tion was criticized as heavily selected (young age, excellent
performance status, mostly “non-head” tumors), not
representing the average “real-life” patient. Subsequent
retrospective clinical analyses confirmed the substantial
toxicity profile, and modifications of the regimen are
commonly recommended [16–18]. In 2013, therapeutic
options further increased with publication of the MPACT
trial. In this study, the addition of nab-paclitaxel to gemci-
tabine therapy increased the median overall survival from
6.6 to 8.7 months [19].
Thus, oncologists might be reluctant to apply FOLFIR-
INOX to older patients. Given the undoubted advan-
tages in response rate and survival, older cancer patients
might be at risk for therapeutic disparity and undertreat-
ment. We conducted a retrospective analysis of patients
with advanced pancreatic cancer under palliative first-
line treatment with FOLFIRINOX at the National Center
for Tumor Diseases, Heidelberg, to assess efficacy and
toxicity in academic practice, especially focusing on
older patients.
Methods
Patients
Requirements for inclusion were (1) histologically
proven diagnosis of ductal pancreatic adenocarcinoma,
(2) irresectable (metastasized or locally advanced) dis-
ease and (3) palliative first-line treatment with FOLFIRI-
NOX at the NCT Heidelberg, Germany between January
2010 and June 2014. The observation period for each pa-
tient started with initiation of first-line treatment (i.e.
first systemic chemotherapy after primary diagnosis of
metastatic or inoperable disease or, in resected patients,
after diagnosis of recurrence). The follow-up period for
this analysis ended on July, 15th 2015. Survival data were
available for all patients. The patients were identified
with permission of two own institutional databases (the
NCT clinical cancer registry, a prospectively maintained
database and the registry of the pharmacy department of
the University hospital Heidelberg, respectively).
Treatment
Full dose FOLFIRINOX consisted of oxaliplatin 85 mg/m2,
irinotecan 180 mg/m2, leucovorin 400 mg/m2, fluorouracil
400 mg/m2 bolus and 2400 mg/m2 over 46 h, q2w, as
originally described [13]. Dose modifications were at the
discretion of the treating physician.
Assessment
Clinical data were documented via an electronic medical
record system. Information included Eastern Cooperative
Oncology Group performance status (ECOG PS) [20],
presence and site of metastases at diagnosis, date of previ-
ous surgery and adjuvant chemotherapy, start and stop
date of FOLFIRINOX treatment, type and severity of
toxicities and consecutive dose reductions, response to
first-line therapy, date of progression, and date of death.
Toxic effects were registered according to the National
Cancer Institute’s common terminology criteria for ad-
verse events (CTCAE). Tumor response was routinely
evaluated according to the response evaluation criteria in
solid tumors (RECIST, [21]).
Statistical analysis
Man Whitney U-Test and Fisher’s exact test were used
for comparing independent samples of quantitative and
binary data, respectively. Progression-free survival (PFS)
was defined as time from start of palliative first-line
treatment to documented tumor progression or death.
Overall survival (OS) was defined as the time from start
of palliative first-line treatment to death. Time-to event
data were analyzed using standard methods, including
Kaplan-Meier product-limit estimates. All analyses of
prognostic factors were of an exploratory nature. Statis-
tical analysis was performed using the SPSS statistical
software, Version 22.
Results
Patients’ demographics
We identified 88 patients meeting the inclusion criteria.
Median duration of observation was 10.4 months. The
median age at diagnosis of advanced disease was 56 years
(range 32–78), 15 patients (17%) were 65 years or older,
and 8 patients (9%) were ≥70 years. 80 patients (91%)
had died at the time of analysis. 50 patients (57%) had
pancreatic head tumors, and 79 patients (90%) had
metastatic disease. 22 patients (25%) had undergone
prior tumor resection, and 13 (15%) had initially re-
ceived adjuvant chemotherapy. 85 patients (97%) started
therapy with an ECOG of 0 or 1. The main characteris-
tics concerning both tumor disease and patient demo-
graphics did not differ significantly between younger (<
65 years) and older (≥ 65 years) patients. The patient
characteristics are summarized in Table 1.
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FOLFIRINOX and toxicities
Median duration of first-line therapy with FOLFIRI-
NOX was 150 days (range 14–787). Thirty-eight
patients (43%) received therapy per protocol without
any modifications during the course of treatment.
Forty-six patients (52%) developed side effects that
were classified as CTCAE grade 3 or higher: Hematologic
side effects were found in 11 patients (13%), and 8 (9%)
developed severe peripheral neuropathy. Six patients (7%)
suffered from severe diarrhea, fatigue or cholangitis, re-
spectively. Seven patients (8%) stopped therapy due to
toxicity. There was no therapy-related death. Modifica-
tions of the FOLFIRINOX protocol were necessary in 50
patients. Median time to the first reduction was 74 days
(range 0–287) after initiation of therapy. 12 patients
(13.6%) had dosage modifications of only oxaliplatin of
which 7 totally stopped and 5 continued therapy with
80% dosage. In 7 patients (8.0%), solely irinotecan,
and in 5 patients (5.7%) the 5-fluorouracil bolus was
dropped. 12 patients (13.6%) had a fixed reduction of
all 3 cytotoxic drugs of 75–80% of the per-protocol
dosage. 12 patients (13.6%) had dose reduction of
varying degrees of two (4 patients) or three compo-
nents (8 patients).
A summary of CTCAE Grade 3 and 4 toxicities is
given in Table 2.
Progression and survival
Median PFS of our cohort was 6.4 months [95% CI
5.7;7.2]. It differed significantly between the ECOG
groups: it was 6.9 months [95% CI 6.2;7.6] for patients
with an ECOG PS 0, 5.4 months [95% CI 3.8;6.9] for
ECOG PS 1 and 2.3 months [95% CI 1.0;3.6] for ECOG
PS 2 (overall comparison p = 0.019) (Fig. 1). Patients
needing dose reductions had a longer median PFS than
those in the per-protocol group (7.4 months [95% CI
5.6;9.2] vs. 3.8 months [95% CI 0.9;6.8]; p = 0.003),
however duration of therapy was significantly longer in
this group: 180 days vs. 59 days (p < 0.001). Patients with
therapy discontinuation due to toxicity had a significantly
shorter PFS (2.5 months [95% CI 1.3;3.8] vs. 6.7 months
[95% CI 6.0;7.4] p = 0.01). There were no apparent PFS
associations for metastasized compared to locally advanced
tumors or for different tumor localizations.
Median OS in our patients was 10.2 months [95%
CI 7.1;13.3], and also differed significantly between
the ECOG groups with 11.8 months [95% CI 11.0;12.6] for
ECOG PS 0, 7.9 months [95% CI 6.4;9.3] for ECOG PS 1
and 3.6 months [95% CI 2.4;4.8] for ECOG PS 2 (overall
comparison p = 0.003) (Fig. 2). While dose modifications
did not significantly influence OS (p = 0.078), patients with
permanent therapy discontinuation due to toxicity lived
significantly shorter (2.8 months [95% CI 2.3;3.3] vs.
11.5 months [95% CI 9.6;13.4], p < 0.001). OS did not sig-
nificantly differ between the groups of patients with
metastasized compared to locally advanced tumors or for
different tumor localizations.
Comparison of different age groups
When we compared older patients (≥ 65 years) and
younger patients, we did not find significant differences
Table 1 Patient characteristics
Patient characteristics all <65 years ≥ 65 years
Number of Patients 88 73 15
Median age (range), years 56 (32–78)
n (%)
Gender
Female 31 (35.2) 29 (39.7) 2 (13.3)
Male 57 (64.8) 44 (60.3) 13 (86.7)
ECOG PS
0 49 (55.7) 43 (58.9) 6 (40.0)
1 36 (40.9) 27 (37.0) 9 (60.0)
2 3 (3.4) 3 (4.1) 0
Metastatic disease 79 (89.8) 64 (87.7) 15 (100.0)
Locally advanced tumor 9 (10.2) 9 (12.3) 0
Primary palliative treatment 66 (75.0) 55 (75.3) 11 (73.3)
Previous resection 22 (25.0) 18 (24.7) 4 (26.7)
Prior (neo-) adjuvant CTX 13 (14.8) 11 (15.1) 2 (13.3)
Site of Tumor
Pancreatic head 50 (56.8) 42 (57.5) 8 (53.3)
Pancreatic corpus 22 (25.0) 20 (27.4) 2 (13.3)
Pancreatic tail 16 (18.2) 11 (15.1) 5 (33.3)
Table 2 Grade 3 or 4 toxicity according to the CTCAE
(version 4)
all, n (%) <65 years ≥ 65 years
Any grade≥ 3 toxicity 46 (52.3) 41 (56.2) 5 (33.3)
Hematological toxicity grade≥ 3
Neutropenia 2 (2.3) 2 (2.7) 0
Febrile neutropenia 1 (1.1) 1 (1.4) 0
Thrombopenia/Anemia 3 (3.4) 3 (4.1) 0
Fatigue 6 (6.8) 4 (5.5) 2 (13.3)
Nausea/Vomiting 3 (3.4) 1 (1.4) 2 (13.3)
Diarrhea 6 (6.8) 5 (6.8) 1 (6.7)
Cholangitis 6 (6.8) 5 (6.8) 1 (6.7)
Thrombosis/Pulmonary embolism 18 (20.5) 17 (23.3) 1 (6.7)
Treatment modifications due to
tocixity
50 (56.8) 43 (58.9) 7 (46.7)
Permanent treatment stop due to
toxicity
7 (8.0) 4 (5.5) 3 (20.0)
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in frequency of therapy interruptions, dosage modifica-
tions, or appearance of any toxicity CTCAE grade 3 or
higher (Table 2). An age ≥ 65 years was not associated
with significantly different PFS or OS. Median OS of
patients ≥65 years was 7.9 months [95% CI 5.8;10.0]
compared to 11.2 months [95%CI 8.9;13.6] for patients
aged younger than 65 years, but this difference was not
significant (p = 0.83).
Discussion
In the U.S., the median age at diagnosis of pancreatic
cancer is 71 years (data for 2006–2010, seer.cancer.gov).
Fig. 1 PFS according to ECOG PS
Fig. 2 OS according to ECOG PS
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Two-thirds of patients are 65 years and older, and 41%
are even 75 years or older. However, the FOLFIRINOX
trial excluded patients older than 75 years (median age
61), and the vast majority of patients was even younger
than 66 years (71%, 244 out of 342). Similarly, other
clinical trials establishing the standard treatments for
advanced pancreatic cancer had median ages between 62
and 64 years [12, 22, 23]. Although the MPACT trial
introducing nab-paclitaxel + gemcitabine did not have
an age limit, median age was also 63 years (range 27–
88), with 42% of patients older than 65 years and 10% of
patients older than 75 years [24].
In our heterogeneous academic outpatient collective, the
survival times for first-line FOLFIRINOX treatment were
in good accordance with the PRODIGE 4 trial collective
and other retrospective analyses [17, 18]. 57% of our
patients needed dose reductions, confirming the regimen’s
substantial toxicity profile. Several authors have recom-
mended using modified FOLFIRINOX regimens with
reduced doses of chemotherapy to decrease the frequency
of side effects. In our cohort, survival times for patients
with dose reductions were not inferior to those receiving
full-dose FOLFIRINOX, supporting the thesis that dose
reductions might be possible without reducing efficacy
[25]. The superior PFS of our patients with protocol
adjustments is probably associated with the fact that dose
reductions occurred more frequently in patients with a
longer treatment period, reflecting the cumulative toxicity
with prolonged chemotherapy. It might be a reasonable
approach to start with full-dose FOLFIRINOX but to care-
fully monitor side effects and quickly adapt the doses if
necessary. In patients that are deemed borderline fit for
FOLFIRINOX, it might be wise to immediately start with a
reduced dose to avoid toxicity-induced treatment discon-
tinuation since this seems to be associated with a worse
outcome. In terms of toxicities, no data for the different
age groups were reported by the PRODIGE 4 trial authors.
We did not find evidence that the subgroup of patients
≥65 years that was initially deemed fit enough for
FOLFIRINOX treatment had an increased incidence of
toxicities. In the PRODIGE 4 trial, the subgroup ana-
lysis showed no hint for a worse survival for patients
between 65 and 74 years [13] and also in our analysis,
the difference in OS for the age groups did not reach
statistical significance. However, the small sample size
of our old patients should be noted.
For gemcitabine-based palliative regimes, we have pre-
viously found that older patients with advanced pancre-
atic cancer with an ECOG PS of 0 or 1 do not have an
inferior outcome or more toxicities than younger pa-
tients [26]. These findings are consistent with studies in
other solid malignancies [27–29]. Thus, for advanced
pancreatic cancer, the feasibility and efficacy of modern
palliative chemotherapy regimens seems to be
independent of chronological age. Our analysis high-
lights the prognostic impact of the initial ECOG PS,
which allows a rapid evaluation of the patients´ re-
sources with respect to tumor-specific treatment. In the
pivotal PRODIGE 4 trial, only patients with an ECOG
PS of 0 or 1 were included, and the MPACT trial in-
cluded less than 10% of patients with an Karnofsky-
score of less than 80%. Contrasting clinical trials with
very strict inclusion criteria, “real-life” analyses include
patients with more comorbidities and/or a reduced gen-
eral condition. However, differences in the rated ECOG
score between different physicians as well as different
medical disciplines have been observed [30]. There is no
doubt that older patients will have on average a worse
ECOG PS and more comorbidities than younger pa-
tients, but the decision to withhold FOLFIRINOX from
old patients based only on chronological age would not be
reasonable and reflects a form of “ageism”. Whether a more
intensive comprehensive geriatric assessment will translate
into a superior rating regarding the tolerability of onco-
logical treatment remains unknown. Some authors suggest
that gemcitabine + nab-paclitaxel might be the preferred
option in older patients given the lower incidence of several
adverse events such as diarrhea in comparison to FOLFIRI-
NOX. However, although independent phase III trials
should only be directly compared very cautiously, the me-
dian overall survival rates clearly favor the FOLFIRINOX
protocol (median OS 11.1 months for FOLFIRINOX vs.
8.7 months for gemcitabine/nab-paclitaxel) and this active
combination should therefore be considered as a valuable
treatment option for old patients in good PS.
The main limitation of our study is the small number
of older patients and the retrospective, non-randomized
nature of the analysis. It seems unlikely that a new
randomized study on FOLFIRINOX in older patients
will formally prove the benefit compared to gemcitabine
monotherapy or gemcitabine/nab-paclitaxel in this
patient group, but our study could serve as an encour-
agement to offer FOLFIRINOX also to older patients
with good performance status. Finally, larger retrospect-
ive analyses, e.g. from cancer registers, might put our
conclusions on a more solid fundament.
Conclusion
Our single-center experience confirms the FOLFIRINOX
protocol being associated with a high rate of substantial
side effects requiring dose reductions in more than half of
the patients. We find some evidence, that dose reductions
are possible without reducing clinical efficacy. Additionally,
FOLFIRINOX seems to be a safe and efficient regimen for
selected old patients with a good ECOG PS. It should not
be withhold from patients solely based on the chronological
age, avoiding any form of “ageism”.
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